Which has preferable earnings & valuation, LUNG or RXST?

RxSight has higher revenue and earnings than Pulmonx. RxSight is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulmonx $90.50M 0.71 -$54M -$1.30 N/A RxSight $134.48M 1.47 -$38.94M -$1.13 N/A

Is LUNG or RXST more profitable?

RxSight has a net margin of -36.58% compared to Pulmonx's net margin of -60.09%. RxSight's return on equity of -17.01% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Pulmonx -60.09% -92.94% -39.80% RxSight -36.58% -17.01% -15.12%

Does the media favor LUNG or RXST?

In the previous week, Pulmonx and Pulmonx both had 2 articles in the media. Pulmonx's average media sentiment score of 0.94 beat RxSight's score of 0.93 indicating that Pulmonx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulmonx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RxSight 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PROF or LUNG more profitable?

Pulmonx has a net margin of -60.09% compared to Profound Medical's net margin of -206.76%. Profound Medical's return on equity of -78.88% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Profound Medical -206.76% -78.88% -64.06% Pulmonx -60.09% -92.94% -39.80%

Is LUNG or OBIO more profitable?

Pulmonx has a net margin of -60.09% compared to Orchestra BioMed's net margin of -166.96%. Pulmonx's return on equity of -92.94% beat Orchestra BioMed's return on equity. Company Net Margins Return on Equity Return on Assets Pulmonx -60.09% -92.94% -39.80% Orchestra BioMed -166.96% -157.46% -60.18%

Does the media prefer LUNG or OBIO?

In the previous week, Orchestra BioMed had 4 more articles in the media than Pulmonx. MarketBeat recorded 6 mentions for Orchestra BioMed and 2 mentions for Pulmonx. Pulmonx's average media sentiment score of 0.94 beat Orchestra BioMed's score of 0.45 indicating that Pulmonx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulmonx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Orchestra BioMed 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LUNG or STEX?

In the previous week, Biosig Technologies had 3 more articles in the media than Pulmonx. MarketBeat recorded 5 mentions for Biosig Technologies and 2 mentions for Pulmonx. Pulmonx's average media sentiment score of 0.94 beat Biosig Technologies' score of 0.54 indicating that Pulmonx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulmonx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biosig Technologies 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LUNG or LUCD more profitable?

Pulmonx has a net margin of -60.09% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Pulmonx -60.09% -92.94% -39.80% Lucid Diagnostics -876.72% N/A -116.26%

Pulmonx (LUNG) Competitors

$1.52 -0.09 (-5.59%)

Closing price 04:00 PM Eastern

Extended Trading

$1.52 +0.00 (+0.33%)

As of 04:10 PM Eastern

Compare

LUNG vs. RXST, PROF, OBIO, STEX, and LUCD

Should you buy Pulmonx stock or one of its competitors? MarketBeat compares Pulmonx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pulmonx include RxSight (RXST), Profound Medical (PROF), Orchestra BioMed (OBIO), Biosig Technologies (STEX), and Lucid Diagnostics (LUCD). These companies are all part of the "medical equipment" industry.

How does Pulmonx compare to RxSight?

Pulmonx (NASDAQ:LUNG) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

RxSight has a net margin of -36.58% compared to Pulmonx's net margin of -60.09%. RxSight's return on equity of -17.01% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-60.09%	-92.94%	-39.80%
RxSight	-36.58%	-17.01%	-15.12%

Pulmonx currently has a consensus price target of $5.58, indicating a potential upside of 267.32%. RxSight has a consensus price target of $9.44, indicating a potential upside of 97.17%. Given Pulmonx's stronger consensus rating and higher possible upside, equities research analysts clearly believe Pulmonx is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93

RxSight has higher revenue and earnings than Pulmonx. RxSight is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.71	-$54M	-$1.30	N/A
RxSight	$134.48M	1.47	-$38.94M	-$1.13	N/A

In the previous week, Pulmonx and Pulmonx both had 2 articles in the media. Pulmonx's average media sentiment score of 0.94 beat RxSight's score of 0.93 indicating that Pulmonx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmonx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RxSight	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 6.8% of Pulmonx shares are owned by insiders. Comparatively, 10.1% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Pulmonx has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market. Comparatively, RxSight has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

Summary

RxSight beats Pulmonx on 9 of the 15 factors compared between the two stocks.

How does Pulmonx compare to Profound Medical?

Profound Medical (NASDAQ:PROF) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Pulmonx has a net margin of -60.09% compared to Profound Medical's net margin of -206.76%. Profound Medical's return on equity of -78.88% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profound Medical	-206.76%	-78.88%	-64.06%
Pulmonx	-60.09%	-92.94%	-39.80%

Profound Medical presently has a consensus price target of $12.00, indicating a potential upside of 83.21%. Pulmonx has a consensus price target of $5.58, indicating a potential upside of 267.32%. Given Pulmonx's stronger consensus rating and higher possible upside, analysts clearly believe Pulmonx is more favorable than Profound Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pulmonx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Pulmonx had 1 more articles in the media than Profound Medical. MarketBeat recorded 2 mentions for Pulmonx and 1 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.94 equaled Pulmonx'saverage media sentiment score.

Company	Overall Sentiment
Profound Medical	Positive
Pulmonx	Positive

Profound Medical has higher earnings, but lower revenue than Pulmonx. Profound Medical is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$16.10M	14.78	-$42.57M	-$1.24	N/A
Pulmonx	$90.50M	0.71	-$54M	-$1.30	N/A

Profound Medical has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Pulmonx has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

47.9% of Profound Medical shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by insiders. Comparatively, 6.8% of Pulmonx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Pulmonx beats Profound Medical on 10 of the 15 factors compared between the two stocks.

How does Pulmonx compare to Orchestra BioMed?

Pulmonx (NASDAQ:LUNG) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are held by institutional investors. 6.8% of Pulmonx shares are held by insiders. Comparatively, 7.5% of Orchestra BioMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Orchestra BioMed has lower revenue, but higher earnings than Pulmonx. Orchestra BioMed is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.71	-$54M	-$1.30	N/A
Orchestra BioMed	$33.48M	6.90	-$52.70M	-$0.97	N/A

Pulmonx currently has a consensus target price of $5.58, indicating a potential upside of 267.32%. Orchestra BioMed has a consensus target price of $13.60, indicating a potential upside of 252.33%. Given Pulmonx's higher probable upside, equities analysts plainly believe Pulmonx is more favorable than Orchestra BioMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Pulmonx has a net margin of -60.09% compared to Orchestra BioMed's net margin of -166.96%. Pulmonx's return on equity of -92.94% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-60.09%	-92.94%	-39.80%
Orchestra BioMed	-166.96%	-157.46%	-60.18%

In the previous week, Orchestra BioMed had 4 more articles in the media than Pulmonx. MarketBeat recorded 6 mentions for Orchestra BioMed and 2 mentions for Pulmonx. Pulmonx's average media sentiment score of 0.94 beat Orchestra BioMed's score of 0.45 indicating that Pulmonx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmonx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Orchestra BioMed	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pulmonx has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

Summary

Pulmonx and Orchestra BioMed tied by winning 8 of the 16 factors compared between the two stocks.

How does Pulmonx compare to Biosig Technologies?

Pulmonx (NASDAQ:LUNG) and Biosig Technologies (NASDAQ:STEX) are both small-cap medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Biosig Technologies has a net margin of 0.00% compared to Pulmonx's net margin of -60.09%. Pulmonx's return on equity of -92.94% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-60.09%	-92.94%	-39.80%
Biosig Technologies	N/A	-717.92%	-336.75%

Pulmonx currently has a consensus price target of $5.58, suggesting a potential upside of 267.32%. Biosig Technologies has a consensus price target of $8.00, suggesting a potential upside of 647.66%. Given Biosig Technologies' higher probable upside, analysts clearly believe Biosig Technologies is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 7.2% of Biosig Technologies shares are held by institutional investors. 6.8% of Pulmonx shares are held by insiders. Comparatively, 52.7% of Biosig Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Pulmonx has higher revenue and earnings than Biosig Technologies. Pulmonx is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.71	-$54M	-$1.30	N/A
Biosig Technologies	$40K	4,863.15	-$462.77M	-$9.71	N/A

Pulmonx has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, Biosig Technologies has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market.

In the previous week, Biosig Technologies had 3 more articles in the media than Pulmonx. MarketBeat recorded 5 mentions for Biosig Technologies and 2 mentions for Pulmonx. Pulmonx's average media sentiment score of 0.94 beat Biosig Technologies' score of 0.54 indicating that Pulmonx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmonx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biosig Technologies	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Pulmonx beats Biosig Technologies on 9 of the 16 factors compared between the two stocks.

How does Pulmonx compare to Lucid Diagnostics?

Pulmonx (NASDAQ:LUNG) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 6.8% of Pulmonx shares are held by insiders. Comparatively, 6.8% of Lucid Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Pulmonx had 1 more articles in the media than Lucid Diagnostics. MarketBeat recorded 2 mentions for Pulmonx and 1 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 1.62 beat Pulmonx's score of 0.94 indicating that Lucid Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Pulmonx	Positive
Lucid Diagnostics	Very Positive

Pulmonx has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

Pulmonx currently has a consensus price target of $5.58, suggesting a potential upside of 267.32%. Lucid Diagnostics has a consensus price target of $4.13, suggesting a potential upside of 310.45%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Pulmonx has a net margin of -60.09% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-60.09%	-92.94%	-39.80%
Lucid Diagnostics	-876.72%	N/A	-116.26%

Pulmonx has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.71	-$54M	-$1.30	N/A
Lucid Diagnostics	$4.71M	43.33	-$58.01M	-$0.47	N/A

Summary

Pulmonx and Lucid Diagnostics tied by winning 7 of the 14 factors compared between the two stocks.

Get Pulmonx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUNG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LUNG vs. The Competition

Export

Metric	Pulmonx	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$68M	$1.57B	$6.47B	$12.54B
Dividend Yield	N/A	N/A	2.69%	5.22%
P/E Ratio	-1.17	77.62	22.39	24.18
Price / Sales	0.71	6.92	520.79	112.26
Price / Cash	N/A	22.87	41.34	57.13
Price / Book	1.16	4.77	9.84	6.72
Net Income	-$54M	-$54.76M	$3.57B	$337.19M
7 Day Performance	-1.30%	-0.78%	-1.16%	0.48%
1 Month Performance	12.59%	4.20%	3.85%	5.07%
1 Year Performance	-52.20%	-3.40%	27.40%	34.25%

Pulmonx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LUNG Pulmonx	2.9064 of 5 stars	$1.52 -5.6%	$5.58 +267.3%	-48.6%	$68M	$90.50M	N/A	250
RXST RxSight	3.2682 of 5 stars	$6.09 flat	$9.44 +55.1%	-68.2%	$251.90M	$134.48M	N/A	220
PROF Profound Medical	2.1528 of 5 stars	$6.83 flat	$12.00 +75.7%	+18.0%	$248.19M	$16.10M	N/A	150
OBIO Orchestra BioMed	4.5851 of 5 stars	$4.06 flat	$13.60 +235.0%	+23.7%	$243.12M	$33.48M	N/A	4	News Coverage Positive News
STEX Biosig Technologies	2.488 of 5 stars	$1.28 flat	$8.00 +525.0%	N/A	$231.86M	$40K	N/A	50	News Coverage Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LUNG) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulmonx (LUNG) Competitors

LUNG vs. RXST, PROF, OBIO, STEX, and LUCD

How does Pulmonx compare to RxSight?

Summary

How does Pulmonx compare to Profound Medical?

Summary

How does Pulmonx compare to Orchestra BioMed?

Summary

How does Pulmonx compare to Biosig Technologies?

Summary

How does Pulmonx compare to Lucid Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUNG vs. The Competition

Pulmonx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pulmonx (LUNG) Competitors

LUNG vs. RXST, PROF, OBIO, STEX, and LUCD

How does Pulmonx compare to RxSight?

Is LUNG or RXST more profitable?

Do analysts prefer LUNG or RXST?

Which has preferable earnings & valuation, LUNG or RXST?

Does the media favor LUNG or RXST?

Do institutionals and insiders have more ownership in LUNG or RXST?

Which has more volatility and risk, LUNG or RXST?

Summary

How does Pulmonx compare to Profound Medical?

Is PROF or LUNG more profitable?

Do analysts recommend PROF or LUNG?

Does the media prefer PROF or LUNG?

Which has better earnings and valuation, PROF or LUNG?

Which has more volatility and risk, PROF or LUNG?

Do insiders & institutionals believe in PROF or LUNG?

Summary

How does Pulmonx compare to Orchestra BioMed?

Do insiders and institutionals have more ownership in LUNG or OBIO?

Which has preferable valuation & earnings, LUNG or OBIO?

Do analysts rate LUNG or OBIO?

Is LUNG or OBIO more profitable?

Does the media prefer LUNG or OBIO?

Which has more risk and volatility, LUNG or OBIO?

Summary

How does Pulmonx compare to Biosig Technologies?

Is LUNG or STEX more profitable?

Do analysts prefer LUNG or STEX?

Do insiders and institutionals have more ownership in LUNG or STEX?

Which has better valuation & earnings, LUNG or STEX?

Which has more volatility and risk, LUNG or STEX?

Does the media prefer LUNG or STEX?

Summary

How does Pulmonx compare to Lucid Diagnostics?

Do institutionals & insiders have more ownership in LUNG or LUCD?

Does the media favor LUNG or LUCD?

Which has more volatility & risk, LUNG or LUCD?

Do analysts prefer LUNG or LUCD?

Is LUNG or LUCD more profitable?

Which has higher valuation & earnings, LUNG or LUCD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUNG vs. The Competition

Pulmonx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools